Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Carey, Paul D.; Vythilingum, Bavanisha; Seedat, Soraya; Muller, Jacqueline E.; van Ameringen, Michael; Stein, Dan J.
January 2005
BMC Psychiatry;2005, Vol. 5, p5
Academic Journal
Background: Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous open-label data has produced mixed results in OCD and additional controlled data is needed. Methods: We undertook a double-blind, randomised, parallel-group, flexible-dose, placebo-controlled study of quetiapine augmentation in subjects who had responded inadequately to open-label treatment with an SRI for 12 weeks. Following informed consent and screening, forty-two subjects were randomised to either placebo or quetiapine for six weeks. Results: There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders. Quetiapine did not demonstrate a significant benefit over placebo at the end of the six-week treatment period (p = .636). Similarly quetiapine failed to separate from placebo in the subgroup of subjects (n = 10) with co-morbid tics. Quetiapine was generally well tolerated. Conclusions: In this study, quetiapine augmentation was no more effective than placebo augmentation of SRIs. A number of limitations in study design make comparisons with previous studies in this area difficult and probably contributed to our negative findings. Future work in this important clinical area should address these limitations.


Related Articles

  • Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder. De Araujo, L. A.; Ito, L. M.; Marks, I. M. // British Journal of Psychiatry;Dec96, Vol. 169, p747 

    Background: Identifying predictors of treatment outcome can suggest ways to improve treatment delivery and understanding of its mechanism of action.Method: Predictors of treatment outcome were sought among 46 out-patients with obsessive-compulsive disorder who completed...

  • Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Lindsay, Merran; Crino, Rocco; Andrews, Gavin; Lindsay, M; Crino, R; Andrews, G // British Journal of Psychiatry;Aug97, Vol. 171, p135 

    Background: Exposure and response prevention is considered a treatment of choice for obsessive-compulsive disorder (OCD). Yet there have been very few randomised controlled trials employing credible placebo conditions. This study compares exposure and response prevention with a...

  • Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Monteiro, W.O.; Noshirvani, H.F.; Marks, I.M.; Lelliott, P.T. // British Journal of Psychiatry;Jul87, Vol. 151, p107 

    Forty-six patients with obsessive-compulsive disorder undergoing a double-blind controlled study of clomipramine and placebo were interviewed to assess changes in sexual function. Of 33 patients with previously normal organism, nearly all of the 24 on clomipramine developed total or partial...

  • Should antidepressants be used to treat childhood depression? Yasong DU // Shanghai Archives of Psychiatry;Feb2013, Vol. 25 Issue 1, p48 

    The author discusses the use of antidepressants to treat childhood depression. He mentions the effectiveness and safety of fluvoxamine and sertraline for treating children with obsessive-compulsive disorder based on several double-blind randomized controlled trials (RCTs). He also cites the need...

  • Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials. Rief, Winfried; Nestoriuc, Yvonne; von Lilienfeld-Toal, Anna; Dogan, Imis; Schreiber, Franziska; Hofmann, Stefan G.; Barsky, Arthur I.; Avorn, Jerry // Drug Safety;2009, Vol. 32 Issue 11, p1041 

    Background: Biases in adverse effect reporting in randomized controlled trials (RCTs) [e.g. due to investigator expectations or assessment quality] can be quantified by studying the rates of adverse events reported in the placebo arms of such trials. Objective: We compared the rates of adverse...

  • Is placebo useful in the treatment of major depression in clinical practice? Marchesi, Carlo; De Panfilis, Chiara; Tonna, Matteo; Ossola, Paolo // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p915 

    Background: For many years, placebo has been defined by its inert content and use in clinical trials. In recent years, several studies have demonstrated its effect in the treatment of major depression. The aim of this paper is to present the conclusions of recent meta-analyses of the placebo...

  • Resistant obsessive compulsive disorder (ROC): predictive factors and links with soft bipolarity. Hantouche, Elie-Georges; Demonfaucon, Christophe; Gerard, Daniel // Annals of General Psychiatry;2006 Supplement 1, Vol. 5, pS141 

    A conference paper on the predictive factors of resistant obsessive compulsive disorder (ROC) and links with soft bipolarity is present. Results suggest that cases with ROC should be explored through specific comorbidity, obsession of appearance and cyclothymic depression, and especially...

  • Fluoxetine/fluvoxamine.  // Reactions Weekly;10/14/2006, Issue 1123, p13 

    The article presents a case report of a woman and a man who developed sexual function disorders during treatment with fluoxetine for dysthymic disorder, and fluvoxamine for obsessive compulsive disorder, respectively. A 35-year-old woman, who reported an enjoyable sex life with intercourse with...

  • Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Stern, R. S.; Marks, I. M.; Mawson, D.; Luscombe, D. K. // British Journal of Psychiatry;Feb80, Vol. 136, p161 

    Forty obsessive-compulsive ritualizers received nightly placebo or clomipramine up to 225 mgs nocte for 8 months, and received behavioural treatment (exposure to vivo) from weeks 4 to 10. Plasma concentrations of clomipramine and its primary metabolite N-desmethylclomipramine steadily increased...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics